Format

Send to

Choose Destination
Urol Oncol. 2018 Nov;36(11):488-497. doi: 10.1016/j.urolonc.2018.08.016. Epub 2018 Sep 27.

Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary update.

Author information

1
Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany. Electronic address: igor.tsaur@unimedizin-mainz.de.
2
Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
3
Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany.
4
Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany.
5
Department of Urology, Fundeni Clinical Institute, University of Medicine and Pharmacy, Carol Davila Bucharest, Bucharest, Romania.
6
Department of Urology, Urological Research Institute, Vita-Salute University and San Raffaele Hospital, Milan, Italy.
7
Department of Urology, Antonius Hospital, Utrecht, The Netherlands.
8
Department of Urology, Martini Klinik, Hamburg, Germany.
9
Department of radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium.
10
Department of Urology, Saint Jean Languedoc Hospital, Toulouse, France and Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.

Abstract

Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease might potentially increase the risk for bone density reduction complications due to a growing efficacy of androgen ablation leading to prolonged exposure. To address both possible indications of combined treatment and to draw practical conclusions, we performed a comprehensive review of the currently available evidence.

KEYWORDS:

Anticancer drugs; Combination therapy; Metastatic; Osteoprotective agents; Prostate cancer; Skeletal events

PMID:
30268712
DOI:
10.1016/j.urolonc.2018.08.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center